Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% S...
Headquartered in Beijing, China, Sino Biological is the world’s leading provider of mammalian cell-based recombinant proteins, antibodies, and relate...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile-- Clover Biopharmaceutica...
Baird Medical's MWA products have been available in China for many years, and the Company is known as a market leader in MWA technology for thyroid and bre...
Over the past few years, exosomes have gained significant attentions as a promising drug delivery vehicle in both academic and biomedical industry circles....
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With...
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type ...
“We took a big step forward in our ongoing commitment to deliver sustainable solutions to our customers, quantifying the impact of our proprietary ap...
Researchers found that fluid therapy guided by non-invasive and continuous PVi can reduce cardiopulmonary complications and infusion. Masimo (NASD...
© 2025 Biopharma Boardroom. All Rights Reserved.
